N-methyl-D-aspartate receptor glycine-binding site (NMDA receptor glycine site)

The **N-methyl-D-aspartate (NMDA) receptor glycine-binding site** is a crucial modulatory site located on the GluN1 subunit of the NMDA receptor, a ligand-gated ion channel within the ionotropic glutamate receptor family[1][3][5]. NMDA receptors are unique among glutamate-activated channels in requiring binding of both glutamate (at the GluN2 subunit) and a co-agonist—glycine or D-serine—at the GluN1 subunit’s glycine-binding site for full activation[5][8][9]. This receptor mediates excitatory synaptic transmission in the central nervous system and plays an essential role in synaptic plasticity, learning, and memory[1][3]. The glycine-binding site is targeted by multiple classes of drugs acting as agonists, partial agonists, antagonists, or allosteric modulators with therapeutic interest for neuropsychiatric and neurodegenerative diseases[2][4][5][9]. Dysregulation of NMDA receptor glycine-site activity has been implicated in schizophrenia, cognitive disorders, neuropathic pain, and epilepsy[1][3][6][9]. Notably, safety concerns such as cognitive impairment and psychotomimetic effects can arise from unbalanced modulation of this site[9].

Other names

glycine site of NMDA receptorNMDA-Gly siteNMDA receptor GluN1 glycine site

Partial agonism at glycine site (e.g., D-cycloserine, GLYX-13) Full agonism at glycine site (glycine, D-serine) Competitive antagonism at glycine site (kynurenic acid, 5,7-dichlorokynurenic acid) Negative allosteric modulation (TCN-201)